CTOs on the Move

Genesis Bioventures

www.gnsbio.com

 
Genesis Bioventures, Inc. is a Surrey, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.gnsbio.com
  • 3033 King George Blvd
    Surrey, BC CAN V4P 1B8
  • Phone: 604.542.0820

Executives

Name Title Contact Details

Similar Companies

Stone Ridge Technology

Stone Ridge Technology is a Bel Air, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MicroBiotix

MicroBiotix is a Worcester, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ImmunoPrecise Antibodies

IPA is a progressive, scientific Contract Research Organization (CRO) recently ranked by one of the pharmaceutical industry`s most trusted, independent market research sources with the highest competitive score, for its antibody service portfolio.1 The company represents a HUB of biotherapeutic intelligence that includes a hybrid of experts and technologies, in the science and business of bioplatform-based discovery. We provide highly specialized full-continuum therapeutic antibody discovery, development, and out-licensing services [Talem] —with advanced omics and complex intelligence technology [LENSai] that provide greater efficiency and accuracy than ever before. Our mission is to provide our pharmaceutical customers with a HUB of the most advanced intelligence and technology to treat disease, bar none. Our goal — is to improve the specificity of biotherapeutics by unlocking the language of the genome.

Abpro

We are a biotechnology company dedicated to developing next-generation antibody therapeutics to improve the lives of patients with severe and life-threatening diseases.

Autolus

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.